Open Nav

Bob Blomquist


Sinfonia Biotherapeutics, Inc.

Bob Blomquist has over 34 years of healthcare industry experience, including senior leadership and operational roles in large corporations and new venture startups. He is the CEO of Sinfonia Biotherapeutics, Inc. He has held executive positions in major healthcare companies (Pharmacia and EG&G Wallac Oy) and founded Wallac Canada Inc. He has a track record of success launching innovative healthcare products and creating new markets. Bob also has a track record of success in acquiring drug and device assets, and intellectual property. He has been an independent board member. Through Blomquist & Associates, Inc., he works as an independent advisor to biotech companies, and private equity investors, and has conducted due diligence for client investments ranging in value up to $500M USD. Bob has developed the first Likelihood Time to Approval database to guide clients. His disease and therapeutic area experience includes neurodegenerative, genetic and orphan diseases and oncology.

This speaker's sessions: